99mTc-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer.

In this report, we present the synthesis and evaluation of the (99m)Tc-labeled beta-Ala-BN(7-14)NH2 (ABN = beta-Ala-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2) as a new radiotracer for tumor imaging in the BALB/c nude mice bearing HT-29 human colon cancer xenografts. The gastrin releasing peptide receptor binding affinity of ABN and HYNIC-ABN (6-hydrazinonicotinamide) was assessed via a competitive displacement of (125)I-[Tyr4]BBN bound to the PC-3 human prostate carcinoma cells. The IC 50 values were calculated to be 24 +/- 2 nM and 38 +/- 1 nM for ABN and HYNIC-ABN, respectively. HYNIC is the bifunctional coupling agent for (99m)Tc-labeling, while tricine and TPPTS (trisodium triphenylphosphine-3,3',3''-trisulfonate) are used as coligands to prepare the ternary ligand complex [(99m)Tc(HYNIC-ABN)(tricine)(TPPTS)] in very high yield and high specific activity. Because of its high hydrophilicity (log P = -2.39 +/- 0.06), [(99m)Tc(HYNIC-ABN)(tricine)(TPPS)] was excreted mainly through the renal route with little radioactivity accumulation in the liver, lungs, stomach, and gastrointestinal tract. The tumor uptake at 30 min postinjection (p.i.) was 1.59 +/- 0.23%ID/g with a steady tumor washout over the 4 h study period. As a result, it had the best T/ B ratios in the blood (2.37 +/- 0.68), liver (1.69 +/- 0.41), and muscle (11.17 +/- 3.32) at 1 h p.i. Most of the injected radioactivity was found in the urine sample at 1 h p.i., and there was no intact [(99m)Tc(HYNIC-ABN)(tricine)(TPPTS)] detectable in the urine, kidney, and liver samples. Its metabolic instability may contribute to its rapid clearance from the liver, lungs, and stomach. Despite the steady radioactivity washout, the tumors could be clearly visualized in planar images of the BALB/c nude mice bearing the HT-29 human colon xenografts at 1 and 4 h p.i. The favorable excretion kinetics from the liver, lungs, stomach, and gastrointestinal tract makes [(99m)Tc(HYNIC-ABN)(tricine)(TPPTS)] a promising SPECT radiotracer for imaging colon cancer.

[1]  Timothy J. Hoffman,et al.  In Vivo Evaluation and Small-Animal PET/CT of a Prostate Cancer Mouse Model Using 64Cu Bombesin Analogs: Side-by-Side Comparison of the CB-TE2A and DOTA Chelation Systems , 2007, Journal of Nuclear Medicine.

[2]  S. Figueroa,et al.  Organometallic 99mTc(III) '4 + 1' bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies. , 2007, Bioconjugate chemistry.

[3]  S. Figueroa,et al.  [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues , 2007, Proceedings of the National Academy of Sciences.

[4]  J. Parry,et al.  In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. , 2007, Bioconjugate chemistry.

[5]  Jason S. Lewis,et al.  Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14). , 2007, Bioconjugate chemistry.

[6]  Young-Seung Kim,et al.  Evaluation of a 99mTc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin αvβ3-Positive Breast Cancer , 2007 .

[7]  Anu T. Singh,et al.  Bombesin analogs containing α‐amino‐isobutyric acid with potent anticancer activity , 2007 .

[8]  A. Beck‐Sickinger,et al.  Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues. , 2007, Nuclear medicine and biology.

[9]  Shuang Liu,et al.  Impact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimer. , 2006, Bioconjugate chemistry.

[10]  Bing Jia,et al.  99mTc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin αvβ3 Expression , 2006 .

[11]  G. Ferro-Flores,et al.  Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours , 2006, Nuclear medicine communications.

[12]  Xianzhong Zhang,et al.  Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. , 2006, Nuclear medicine and biology.

[13]  J. Parry,et al.  MicroPET Imaging of Breast Cancer Using Radiolabeled Bombesin Analogs Targeting the Gastrin-releasing Peptide Receptor , 2006, Breast Cancer Research and Treatment.

[14]  A. Nunn,et al.  Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  S. Mohammed,et al.  Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. , 2005, Bioconjugate chemistry.

[16]  R. Jensen,et al.  Identification of key amino acids in the gastrin-releasing peptide receptor (GRPR) responsible for high affinity binding of gastrin-releasing peptide (GRP). , 2005, Biochemical pharmacology.

[17]  J. Reubi,et al.  Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. , 2005, Journal of medicinal chemistry.

[18]  M. Pomper,et al.  A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. , 2005, Bioconjugate chemistry.

[19]  H. Ohki‐Hamazaki,et al.  Development and function of bombesin-like peptides and their receptors. , 2005, The International journal of developmental biology.

[20]  R. Kazlauskas,et al.  Sports drug testing--an analyst's perspective. , 2004, Chemical Society reviews.

[21]  G. de Vincentis,et al.  Gastrin-releasing peptide (GRP) analogues for cancer imaging. , 2004, Cancer biotherapy & radiopharmaceuticals.

[22]  G. D. Vincentis,et al.  99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  J. Reubi.  Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.

[24]  Joonyoung Kim,et al.  MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. , 2003, Bioconjugate chemistry.

[25]  R. Valkema,et al.  Radiolabelled peptides for tumour therapy: current status and future directions , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  H. Gali,et al.  Radiochemical investigations of (99m)Tc-N(3)S-X-BBN[7-14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. , 2003, Bioconjugate chemistry.

[27]  G. Loudos,et al.  [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  Shuang Liu,et al.  99mTc-Labeling of a hydrazinonicotinamide-conjugated LTB(4) receptor antagonist useful for imaging infection and inflammation. , 2002, Bioconjugate chemistry.

[29]  G. de Vincentis,et al.  Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. , 2002, Cancer biotherapy & radiopharmaceuticals.

[30]  R. Schibli,et al.  A 99mTc(I)-postlabeled high affinity bombesin analogue as a potential tumor imaging agent. , 2002, Bioconjugate chemistry.

[31]  J. Barrett,et al.  99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. , 2001, Bioconjugate chemistry.

[32]  G. Slegers,et al.  Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging? , 2001, Nuclear medicine communications.

[33]  W. Oyen,et al.  A 99Tcm-labelled leukotriene B4 receptor antagonist for scintigraphic detection of infection in rabbits , 2000, Nuclear medicine communications.

[34]  G. Slegers,et al.  Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study , 2000, European Journal of Nuclear Medicine.

[35]  R. Benya,et al.  Characterization of gastrin-releasing peptide and its receptor aberrantly expressed by human colon cancer cell lines. , 2000, Molecular pharmacology.

[36]  Shuang Liu,et al.  99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals. , 1999, Chemical reviews.

[37]  G. Bridger,et al.  RP463: a stabilized technetium-99m complex of a hydrazino nicotinamide derivatized chemotactic peptide for infection imaging. , 1999, Bioconjugate chemistry.

[38]  H. Gali,et al.  99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent. , 1999, Bioconjugate chemistry.

[39]  J. Barrett,et al.  99mTc labeling of highly potent small peptides. , 1997, Bioconjugate chemistry.

[40]  J. Barrett,et al.  New and versatile ternary ligand system for technetium radiopharmaceuticals: water soluble phosphines and tricine as coligands in labeling a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with 99mTc. , 1997, Bioconjugate chemistry.

[41]  D. Payan,et al.  Direct Observation of Endocytosis of Gastrin Releasing Peptide and Its Receptor (*) , 1995, The Journal of Biological Chemistry.

[42]  A. Schally,et al.  The Binding of Bombesin and Somatostatin and Their Analogs to Human Colon Cancers , 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[43]  R. Jensen,et al.  Development of a potent bombesin receptor antagonist with prolonged in vivo inhibitory activity on bombesin-stimulated amylase and protein release in the rat , 1992, Peptides.

[44]  J. Minna,et al.  High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. , 1985, Life sciences.

[45]  V. Erspamer,et al.  Some pharmacological actions of alytesin and bombesin , 1970, The Journal of pharmacy and pharmacology.